151 related articles for article (PubMed ID: 24564321)
1. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening.
Ballante F; Caroli A; Wickersham RB; Ragno R
J Chem Inf Model; 2014 Mar; 54(3):956-69. PubMed ID: 24564321
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application.
Caroli A; Ballante F; Wickersham RB; Corelli F; Ragno R
J Chem Inf Model; 2014 Mar; 54(3):970-7. PubMed ID: 24555544
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
Sakkiah S; Thangapandian S; John S; Lee KW
Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
[TBL] [Abstract][Full Text] [Related]
5. Molecular design of anticancer drug leads based on three-dimensional quantitative structure-activity relationship.
Huang XY; Shan ZJ; Zhai HL; Li LN; Zhang XY
J Chem Inf Model; 2011 Aug; 51(8):1999-2006. PubMed ID: 21755987
[TBL] [Abstract][Full Text] [Related]
6. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
8. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore assessment through 3-D QSAR: evaluation of the predictive ability on new derivatives by the application on a series of antitubercular agents.
Friggeri L; Ballante F; Ragno R; Musmuca I; De Vita D; Manetti F; Biava M; Scipione L; Di Santo R; Costi R; Feroci M; Tortorella S
J Chem Inf Model; 2013 Jun; 53(6):1463-74. PubMed ID: 23617317
[TBL] [Abstract][Full Text] [Related]
10. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
11. QSAR Studies to Predict Activity of HSP90 Inhibitors.
Patil VM; Masand N; Gupta SP; Blagg BSJ
Curr Top Med Chem; 2021; 21(25):2272-2291. PubMed ID: 34635040
[TBL] [Abstract][Full Text] [Related]
12. Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.
Kung PP; Sinnema PJ; Richardson P; Hickey MJ; Gajiwala KS; Wang F; Huang B; McClellan G; Wang J; Maegley K; Bergqvist S; Mehta PP; Kania R
Bioorg Med Chem Lett; 2011 Jun; 21(12):3557-62. PubMed ID: 21612924
[TBL] [Abstract][Full Text] [Related]
13. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.
Knox AJ; Price T; Pawlak M; Golfis G; Flood CT; Fayne D; Williams DC; Meegan MJ; Lloyd DG
J Med Chem; 2009 Apr; 52(8):2177-80. PubMed ID: 19331414
[TBL] [Abstract][Full Text] [Related]
14. 3-D QSAutogrid/R: an alternative procedure to build 3-D QSAR models. Methodologies and applications.
Ballante F; Ragno R
J Chem Inf Model; 2012 Jun; 52(6):1674-85. PubMed ID: 22643034
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
Saxena AK; Saxena S; Chaudhaery SS
SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
[TBL] [Abstract][Full Text] [Related]
17. How well can fragments explore accessed chemical space? A case study from heat shock protein 90.
Roughley SD; Hubbard RE
J Med Chem; 2011 Jun; 54(12):3989-4005. PubMed ID: 21561141
[No Abstract] [Full Text] [Related]
18. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.
Roy KK; Singh S; Saxena AK
Mol Divers; 2011 May; 15(2):477-89. PubMed ID: 20740314
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Khanfar M; Abudayyh A
J Enzyme Inhib Med Chem; 2016; 31(sup4):64-77. PubMed ID: 27569779
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
